Standard Biotools Beta
| LAB Stock | USD 1.11 0.08 6.72% |
As of the 12th of February 2026, Standard Biotools has the Semi Deviation of 3.42, risk adjusted performance of 0.0203, and Coefficient Of Variation of 6668.1. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Standard Biotools, as well as the relationship between them.
Standard Biotools Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.7092 | Revenue |
Standard | Beta | Build AI portfolio with Standard Stock |
Standard Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Standard Biotools is extremely important. It helps to project a fair market value of Standard Stock properly, considering its historical fundamentals such as Beta. Since Standard Biotools' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Standard Biotools' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Standard Biotools' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Standard Biotools 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Standard Biotools' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Standard Biotools.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Standard Biotools on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Standard Biotools or generate 0.0% return on investment in Standard Biotools over 90 days. Standard Biotools is related to or competes with Varex Imaging, CeriBell, Cullinan Oncology, Avanos Medical, So Young, ADC Therapeutics, and Treace Medical. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researche... More
Standard Biotools Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Standard Biotools' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Standard Biotools upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.79 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 25.5 | |||
| Value At Risk | (6.12) | |||
| Potential Upside | 7.81 |
Standard Biotools Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Standard Biotools' standard deviation. In reality, there are many statistical measures that can use Standard Biotools historical prices to predict the future Standard Biotools' volatility.| Risk Adjusted Performance | 0.0203 | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0389 |
Standard Biotools February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0203 | |||
| Market Risk Adjusted Performance | 0.0489 | |||
| Mean Deviation | 3.08 | |||
| Semi Deviation | 3.42 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 6668.1 | |||
| Standard Deviation | 4.44 | |||
| Variance | 19.67 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0389 | |||
| Maximum Drawdown | 25.5 | |||
| Value At Risk | (6.12) | |||
| Potential Upside | 7.81 | |||
| Downside Variance | 14.38 | |||
| Semi Variance | 11.73 | |||
| Expected Short fall | (3.97) | |||
| Skewness | 1.41 | |||
| Kurtosis | 5.95 |
Standard Biotools Backtested Returns
Standard Biotools owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0181, which indicates the firm had a -0.0181 % return per unit of risk over the last 3 months. Standard Biotools exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Standard Biotools' Coefficient Of Variation of 6668.1, risk adjusted performance of 0.0203, and Semi Deviation of 3.42 to confirm the risk estimate we provide. The entity has a beta of 1.45, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. At this point, Standard Biotools has a negative expected return of -0.0827%. Please make sure to validate Standard Biotools' jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if Standard Biotools performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.27 |
Poor predictability
Standard Biotools has poor predictability. Overlapping area represents the amount of predictability between Standard Biotools time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Standard Biotools price movement. The serial correlation of 0.27 indicates that nearly 27.0% of current Standard Biotools price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.27 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Standard Biotools has a Beta of 1.328. This is 54.42% higher than that of the Life Sciences Tools & Services sector and 7.78% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Standard Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Biotools' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Biotools could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics of similar companies.Standard Biotools is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform.
Standard Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 290.12 M | ||||
| Shares Outstanding | 384.57 M | ||||
| Shares Owned By Insiders | 2.57 % | ||||
| Shares Owned By Institutions | 77.10 % | ||||
| Number Of Shares Shorted | 9.79 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 2.73 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 81.9 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Short Ratio | 6.63 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Price To Earnings To Growth | 0.31 X | ||||
| Target Price | 1.55 | ||||
| Number Of Employees | 814 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 463.4 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
| Net Asset | 612.34 M |
About Standard Biotools Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Biotools's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Biotools using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Biotools based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.